Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Tirzepatide in SURMOUNT ADOLESCENTS

A 72 week randomized trial found that tirzepatide reduced BMI more than placebo in 160 adolescents receiving a shared healthy lifestyle intervention.

Why we wrote this. The first randomized tirzepatide result in adolescents needs a pediatric evidence boundary, complete denominator reporting and restraint where full safety tables are not accessible.

In this article (5 sections)
  1. Who took part and what was tested
  2. The primary BMI result
  3. How to interpret BMI during adolescence
  4. Safety reporting in the accessible record
  5. Strengths and remaining limits

The phase 3 SURMOUNT ADOLESCENTS trial found that tirzepatide reduced body mass index more than placebo over 72 weeks in adolescents with obesity or overweight plus a related complication. The trial randomized 160 participants aged 12 to younger than 18 years. Every participant also received a healthy lifestyle intervention, so the comparison was tirzepatide plus that program against placebo plus the same program[1].

Who took part and what was tested

Investigators conducted the double blind trial at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland and the United States. Enrollment ran from October 2023, and the study concluded in June 2026. Participants had obesity, or overweight with at least one obesity related complication[2].

The 160 participants had a mean age of 14.6 years. Ninety nine, or 61.9%, were female. Mean starting body weight was 109.7 kg and mean BMI was 38.6. Randomization assigned 109 participants to tirzepatide and 51 to placebo in a 2:1 ratio[1].

Tirzepatide was escalated within the protocol to a maximum tolerated weekly dose of 5, 10 or 15 mg. That monitored research procedure is not a dosing instruction. Adolescents require specialist assessment, safeguarding and follow up, and this article cannot determine whether the study regimen is appropriate for any individual.

The primary BMI result

At week 72, mean BMI had fallen 18.5% in the tirzepatide group and risen 0.5% in the placebo group. The estimated treatment difference was -19.0 percentage points, with a 95% confidence interval from -23.9 to -14.1. The p value was below 0.001, meeting the trial's superiority test for the primary endpoint[2].

A BMI reduction of at least 5% was estimated for 79.6% of tirzepatide treated participants and 28.5% of placebo participants. The estimated risk difference was 51.2 percentage points, with a 95% confidence interval from 36.3 to 66.1. The abstract reports that all ten key secondary outcomes significantly favored tirzepatide[1].

Those secondary outcomes included higher BMI reduction thresholds, change in BMI standard deviation score, BMI expressed relative to the 95th percentile, body weight, waist circumference and physical functioning. They describe related but different aspects of change. Statistical significance across them does not make each measure interchangeable or establish a long term clinical outcome.

How to interpret BMI during adolescence

Growth matters. Pediatric BMI is interpreted with age and sex specific references, which is why the trial included BMI standard deviation score and percentage of the 95th percentile alongside ordinary percent change. A lower BMI can reflect treatment effect, but BMI does not directly measure body composition, nutrition, psychological wellbeing or every obesity related complication.

The result is a group average. It does not predict the response of one adolescent, and the threshold analysis shows that responses varied. The study also did not compare tirzepatide with another active obesity medicine. It cannot establish superiority over semaglutide or define which medicine has the best balance for a particular young person.

Safety reporting in the accessible record

The most common adverse events with tirzepatide were gastrointestinal and were mostly mild to moderate. Prespecified safety outcomes included treatment emergent adverse events, serious adverse events and discontinuations due to adverse events. However, the complete PubMed abstract does not print event counts, serious event details or discontinuation numbers[2].

The JAMA full text returned an access challenge to our retrieval route. This readout therefore does not fill those missing safety details from summaries or assumptions. A trial of 160 adolescents over 72 weeks also cannot rule out uncommon harms or answer questions about development, maintenance after discontinuation or outcomes years later.

Weight related care in adolescents can affect physical and psychological health. The trial result should not be converted into unsupervised use, a target imposed on a child or advice to change an existing medicine. Family context, mental health, growth, nutrition, comorbidities and local authorization all belong in individual clinical assessment.

Strengths and remaining limits

Randomization, double blinding and placebo control strengthen the 72 week comparison. A multinational, multicenter design also reduces dependence on one clinic. The active and placebo groups received the same healthy lifestyle intervention, which helps isolate the added effect of assignment within that program.

The modest sample and 2:1 allocation leave only 51 participants in the placebo group. The abstract does not provide results by age, sex, race, baseline complication or final tolerated dose. It also does not expose complete methods for missing data, adherence, puberty related analyses, funding or author conflicts. Those omissions limit subgroup and safety interpretation from the accessible record.

Future evidence needs longer follow up through late adolescence and early adulthood, complete safety reporting, and careful assessment after treatment stops. Active comparator trials would answer a different question from this placebo controlled study. Outcomes beyond BMI should include cardiometabolic disease, physical function, mental health, nutrition and quality of life.

SURMOUNT ADOLESCENTS provides direct randomized evidence for the trial population and duration. It does not erase the need for specialist pediatric care. The broader tirzepatide evidence overview covers other populations, but adult results should not be transferred to adolescents without direct evidence.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

How much did BMI change in SURMOUNT ADOLESCENTS?

Mean BMI decreased 18.5% with tirzepatide and increased 0.5% with placebo at week 72, an estimated difference of -19.0 percentage points.

How many adolescents were included?

The trial randomized 160 adolescents aged 12 to younger than 18 years: 109 to tirzepatide and 51 to placebo.

Did both groups receive lifestyle support?

Yes. Tirzepatide or placebo was added to a healthy lifestyle intervention in both groups, so the result reflects the added treatment effect within that shared program.

What did the trial report about adverse events?

The most common adverse events with tirzepatide were gastrointestinal and mostly mild to moderate. The accessible abstract does not provide the complete safety counts.

Sources

  1. [1]PubMed record for SURMOUNT ADOLESCENTS, PMID 43035096Tier 1 · primary↩
  2. [2]NCBI EFetch abstract for SURMOUNT ADOLESCENTS, PMID 43035096Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars